GO
Loading...

Enter multiple symbols separated by commas

Stocks Abbott Laboratories

More

  • MUMBAI, April 15- India may go to the World Trade Organization if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • Your first trade for Thursday Wednesday, 8 Apr 2015 | 6:14 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Cramer Remix: It's time to buy these oil stocks Wednesday, 1 Apr 2015 | 7:00 PM ET
    Jim Cramer on the set of Mad Money

    The pain may finally be coming to an end for these names, says “Mad Money” host Jim Cramer.

  • Cramer: Watch out! Market's No.1 enemy right now Wednesday, 1 Apr 2015 | 6:12 PM ET
    GoDaddy CEO Blake Irving visits on the floor of the New York Stock Exchange as the website hosting service makes its initial public offering (IPO) on April 1, 2015 in New York.

    Jim Cramer is concerned with the amount of flooding in the market right now, and warns investors to watch out for these signs of a sinking ship.

  • Early movers: SHLD, WMT, GDDY, AAPL & more Wednesday, 1 Apr 2015 | 7:47 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • No bans on NZ dairy products after poison threat -govt Thursday, 12 Mar 2015 | 2:41 AM ET

    Countries including China, the biggest buyer of New Zealand dairy products, were not closing the door on shipments, a top official from the ministry told Reuters, as police track down the sender of letters to dairy giant Fonterra and the national farmers' group which were accompanied by infant formula laced with the pesticide 1080.. Following the announcement...

  • Four trades to go before the closing bell Wednesday, 11 Mar 2015 | 1:29 PM ET

    The "Halftime Report" traders give their final trades of the show.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • *Best Buy climbs after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. It's predicated on the fact that when you get up around new highs market participants tend to get a little vertigo, "said Art Hogan, chief market strategist at Wunderlich Securities in New York.

  • *Best Buy climbs in premarket after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. "The market is naturally settling in, taking a breather until the scales tip either way to commence the next move to continued to new heights or a consolidated pullback," said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • March 2- Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  • Feb 17- Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson& Johnson to settle a long-running lawsuit over Boston Scientific's 2005 acquisition of rival Guidant. J&J had sought more than $7 billion in damages after it lost a bidding war to Boston Scientific following an initial deal to buy Guidant for $21.5...

  • *Wave of inversion deals had many causes, experts say. *Earnings stripping, foreign profits seen as key. WASHINGTON, Feb 9- When a series of big U.S. companies last year moved to reincorporate abroad in inversion deals, some Republican lawmakers and tax policy critics blamed the high U.S. corporate tax rate.

  • Feb 2- Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products. Monday's announcement marks Mylan's second deal with an Indian drugmaker after it bought Bangalore- based Strides Arcolab's injectable drugs unit for...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Abbott Labs 2015 outlook in line with estimates Thursday, 29 Jan 2015 | 11:05 AM ET
    Employees walk near an Abbott Laboratories sign at the company's headquarters complex in Abbott Park, Illinois.

    Abbott Laboratories forecast full-year profit in line with analysts' estimates even as other drugmakers warned of a strong dollar hurting results.

  • Early movers: SNDK, HLT, MET, WWW, AAPL & more Tuesday, 13 Jan 2015 | 7:53 AM ET
    NYSE New York Stock Exchange traders markets

    Some of the names on the move ahead of the open.

  • It's all about oil, the euro and a strong dollar Monday, 5 Jan 2015 | 10:43 AM ET
    A man walks by a euro sign light installation in Vilnius, Lithuania, on Dec. 31, 2014.

    If the weak euro, strong dollar and cheap oil persist, these commodities and stocks will predictably take a hit.